Baseline demographics and disease characteristics
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 63 (51-72) |
| Sex, n | |
| Male | 7 |
| Female | 3 |
| Race and ethnicity, n | |
| White | 8 |
| Asian | 1 |
| Hispanic | 1 |
| Diagnosis, n | |
| Acute leukemia | 5 |
| Myelodysplastic syndrome | 2 |
| Lymphoma | 2 |
| Aplastic anemia | 1 |
| Graft source, n | |
| Peripheral blood stem cells | 10 |
| Donor, n | |
| Matched unrelated | 9 |
| Haploidentical | 1 |
| Conditioning intensity, n | |
| Reduced | 9 |
| Myeloablative | 1 |
| GVHD prophylaxis, n | |
| Tacrolimus/methotrexate with/without other | 9 |
| Posttransplant cyclophosphamide based | 1 |
| Median time from HCT to acute GVHD diagnosis (range), d | 85 (20-207) |
| GVHD treatment history at enrollment | |
| Treatment-naïve | 9 |
| Treatment-refractory | 1 |
| MAGIC GVHD grading at enrollment, n | |
| Grade 3 | 9 |
| Grade 4 | 1 |
| LGI stage at enrollment, n | |
| 2 | 4 |
| 3 | 5 |
| 4 | 1 |
| Minnesota risk score at enrollment, n | |
| High | 10 |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 63 (51-72) |
| Sex, n | |
| Male | 7 |
| Female | 3 |
| Race and ethnicity, n | |
| White | 8 |
| Asian | 1 |
| Hispanic | 1 |
| Diagnosis, n | |
| Acute leukemia | 5 |
| Myelodysplastic syndrome | 2 |
| Lymphoma | 2 |
| Aplastic anemia | 1 |
| Graft source, n | |
| Peripheral blood stem cells | 10 |
| Donor, n | |
| Matched unrelated | 9 |
| Haploidentical | 1 |
| Conditioning intensity, n | |
| Reduced | 9 |
| Myeloablative | 1 |
| GVHD prophylaxis, n | |
| Tacrolimus/methotrexate with/without other | 9 |
| Posttransplant cyclophosphamide based | 1 |
| Median time from HCT to acute GVHD diagnosis (range), d | 85 (20-207) |
| GVHD treatment history at enrollment | |
| Treatment-naïve | 9 |
| Treatment-refractory | 1 |
| MAGIC GVHD grading at enrollment, n | |
| Grade 3 | 9 |
| Grade 4 | 1 |
| LGI stage at enrollment, n | |
| 2 | 4 |
| 3 | 5 |
| 4 | 1 |
| Minnesota risk score at enrollment, n | |
| High | 10 |